SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2015; 32; 188-193

© Mattioli 1885

DIAGNOSTIC EFFICACY OF ULTRASOUND-GUIDED CORE-NEEDLE BIOPSY OF PERIPHERAL LYMPH NODES IN SARCOIDOSIS

S. Boussouar¹, A. Medjhoul¹, J.F. Bernaudin², O. Tayebjee^{1,3}, M. Soussan⁴, Y. Uzunhan^{5,6}, H. Nunes^{5,6}, M. Kambouchner⁷, A. Martin⁸, D. Valeyre^{5,6}, P.Y. Brillet^{1,6}

¹ AP-HP, Department of Radiology, Avicenne Hospital, Bobigny, France; ² AP-HP, Department of Pathology, Avicenne Tenon, Paris, France; ³ Department of Radiology, Hôpital Privé de la Seine Saint-Denis, Le Blanc-Mesnil, France; ⁴ AP-HP, Department of Nuclear Medicine, Avicenne Hospital, Bobigny, France; ⁵ AP-HP, Department of Pneumology, Avicenne Hospital, Bobigny, France; ⁶ Université Paris 13, Sorbonne Paris Cité, EA 2363; ⁷ AP-HP, Department of Pathology, Avicenne Hospital, Bobigny, France

ABSTRACT. *Background:* Core-needle biopsy guided by ultrasound can be performed for investigating peripheral lymph node (PLN). The aim of this study was to determine the efficacy of this technique in sarcoidosis. *Methods:* Retrospective review of files of all patients in the database of the radiology department of Avicenne university hospital who underwent PLN biopsies guided by ultrasound from January 2008 to June 2011 (n=292). Cases with either granulomas at histology with the procedure or with a final diagnosis of sarcoidosis were included in the study. *Results:* The histological specimens were adequate in 282 out of 292 cases (96%) showing non-caseating granulomas in 22 cases (n=20 patients with a final diagnosis of sarcoidosis and n=2 patients with tuberculosis). After reviewing clinical files of the 282 patient, 22 were confirmed to have sarcoidosis, at initial presentation (n=19) or later during flare-up or relapse (n=3) with only 2 patients having no granuloma on PLN biopsy. PLN were palpable in 18 cases and only detected by ^{18F}FDG-PET/CT showing increased PLN uptake in 4 cases. The sensitivity and specificity of adequate biopsy were 91 and 99% and the positive and negative predictive values were 91 and 99%, respectively. *Conclusion:* Core-needle biopsy guided by ultrasound has a high efficacy for evidencing granulomas in sarcoidosis patients with PLN involvement either clinically palpable or in the presence of ^{18F}FDG-PET/CT uptake. *(Sarcoidosis Vasc Diffuse Lung Dis 2015; 31: 188-193)*

KEY WORDS: PET/CT, sarcoidosis, peripheral lymph node, niopsy, granuloma

INTRODUCTION

Sarcoidosis is a systemic granulomatous disorder of unknown cause that most frequently involves the lung and the lymphatic system. The diagnosis is

Accepted after revision: 23 October 2014

Correspondence: Samia Boussouar

AP-HP, Department of Radiology, Avicenne Hospital, Bobigny, France

E-mail: samiaboussouar@gmail.com

established when suggestive clinical and radiological findings are supported by histological evidence of its hallmark, i.e. non-caseating epithelioid cell granulomas, and when other diseases with a similar histological or clinical presentation can be excluded (1, 2). The site for biopsy depends on accessibility, safety, and potential yield of the procedure according to presentation (3). In keeping with these criteria, superficial lesions, including skin lesions other than erythema nodosum, palpable peripheral lymph node (PLN), or visible conjunctival nodules should be considered as the first targets (2).

Presented at the VIth international conference on diffuse lung diseases (WASOG), Paris- la Sorbonne, 6-7 June 2013

Received: 8 July 2014

PLN are clinically detected in about one third of sarcoid patients (4) either at presentation or during follow-up, in relation to flare-up/relapse or comorbid conditions. PLN may represent an accurate site for biopsy, for both the demonstration of granulomatous lesions (5) and the exclusion of differential diagnoses. PLN can be investigated by ultrasound (US) guided core-needle biopsy, which is a minimally invasive and high cost/efficiency technique. Lymph nodes core-needle biopsy has become the method of choice for the diagnosis of lymphoma in many institutions (6, 7) as it provides larger samples than fine-needle aspiration cytology. Surprisingly, the role of PLN core-needle biopsy has not yet been comprehensively assessed for the diagnosis of sarcoidosis, whereas it could be a safe alternative to surgical biopsy and a more informative procedure than fine-needle aspiration cytology (8, 9).

PLN core-needle biopsy could be proposed if PLN are detected during physical examination (palpable PLN) or following imaging investigation, including F18- Fluorodeoxyglucose -Positron Emission Tomography/Computed Tomography (18F-FDG-PET/CT) in patients with suspected sarcoidosis or in sarcoid patients for which the occurrence of a comorbid condition is raised (1, 10). Therefore, the purpose of this study was to evaluate the yield and safety of PLN US guided core-needle biopsy for the diagnosis of sarcoidosis.

MATERIALS AND METHODS

This retrospective study was approved by the institutional review board of our institution and patients received written information. We reviewed all histological and clinical reports of patients who underwent PLN US guided biopsies in the Radiology Department (Avicenne Hospital, Bobigny, France) from January 2008 to June 2011 (n=292 biopsies in 282 patients). Patients with sarcoidosis were all recruited in the same hospital suffering from various pulmonary diseases with PLN involvement. From this database, we focused our attention on the one hand on patients with histological findings of non-caseating granulomas and on the other hand on those who had a final diagnosis of sarcoidosis based on other investigations and clinical follow-up according to the statement on sarcoidosis (11).

PLN US guided Biopsy technique

The biopsies were performed under ultrasound guidance (Aplio 50, Toshiba Medical Systems, Puteaux, France) by a senior radiologist (PYB, OT, AM). A high frequency linear ultrasound probe (> 7.5 MHz) was used to guide the biopsy. Only PLN with a diameter over 10 mm were considered for biopsy. Lidocaine hydrochloride (10 mg/ml Aguettant[®], France) was used for local anaesthesia. Tissue samples were thereafter obtained by means of a 14 to 20 Gauge needle (Temno; CareFusion, San Diego, California, USA), enabling up to a 20 mm long core of tissue to be obtained. For every patient, 1 to 6 samples were taken. Specimens were immediately fixed in formalin and then paraffin-embedded and conventionally processed. A sample was sent for bacteriological analysis and mycobacterial culture in patients at risk for tuberculosis,.

Analysis of clinical, radiological, biopsy processing, and pathological data

The following clinical data were noted: gender, age, history of sarcoidosis (presentation, suspicion of flare-up/relapse or comorbid condition), the presence of palpable PLN, sarcoidosis visceral localizations, and serum angiotensin-converting enzyme level. Imaging data, including ^{18F}FDG-PET/CT were reviewed. Roentgenographic staging of intrathoracic changes was determined according to the sarcoidosis statement (11). Information regarding PLN core-needle biopsies was also reviewed, including the site, number, and size, as well as the occurrence of any adverse event.

The adequacy of the material obtained was also considered. Inadequate results referred to cases with insufficient material for a proper histological diagnosis or non-caseating necrotic tissues (7). When the material was adequate, the different pathological diagnoses were collected.

Statistical analysis

Only patients with adequate samples were included for further statistical analysis. Clinical, radiological, biopsy processing and pathological data were assessed by descriptive statistics. Regarding the diagnosis yield of the core-needle biopsy, sensitivity, specificity, and negative/positive predictive value were calculated. A biopsy result was considered to be true-positive when the tissue sample was adequate and the histologic diagnosis indicated "granulomas without caseating necrosis" with a final diagnosis of sarcoidosis. A false-positive result referred to tissue samples considered adequate with a histological diagnosis indicating "non-caseating granulomas" while the final diagnosis was not sarcoidosis. A false-negative result referred to tissue samples considered adequate where histologic diagnosis indicated "no granuloma" while the final diagnosis was sarcoidosis. A true-negative result referred to other cases of adequate tissue sampling.

RESULTS

Specimens were adequate for histological analysis in 282/292 biopsies (96.5%). No adverse event was observed following the procedure.

The pathological diagnoses are shown in Figure 1. Twenty-two patients had non-caseating granulomas (8%, Figure 2), including 20 patients with a final diagnosis of sarcoidosis and 2 patients with tuberculosis (false positive). After reviewing the clinical files of the 282 patients, 22 were confirmed to



Fig. 2. Histological view (Hematoxylin and eosin stain, x100) of a core-needle lymph node biopsy (patient 1, 16 Gauge). Multiple small epitheloid granulomas with few giant cells are disseminated into the lymphoid tissu, some surrounded by discrete fibrosis. Necrosis is absent

have sarcoidosis. For 20 of these 22 patients (91%, true positive), non-caseating granulomas were observed while the exam was negative showing no granuloma for the remaining 2 cases (false negative). Therefore, the sensitivity and specificity of the coreneedle biopsy were 91% and 99%, respectively, while the positive and negative predictive values were 91% and 99%, respectively.

The clinical characteristics of the sarcoid patients are shown in Table 1. The population consist-



Fig. 1. Study flowchart. Among the 282 patients who underwent 292 Peripheral Lymph Node (PLN) ultrasound-guided core-needle biopsies, 22 had a final diagnosis of sarcoidosis

| Abbreviations: peripheral lymph nodes (PLN), not available (NA), Serum Angiotensin-Converting En- | reased PLN uptake, endobronchial biopsies (EBB), minor salivary gland (MSG). Mediastinoscopy*, EBB*: | confirm sarcoidosis relapse |
|---|--|-----------------------------|
| al lymph | bronchia | se |
| periphera | ake, endc | osis relaps |
| eviations: | PLN upt | n sarcoidc |
| sis. Abbr | increased | to confirr |
| f sarcoido | n cases of | rformed 1 |
| gnostic o | positive i | biopsy pe |
| a final dia | onsidered | vith PLN |
| its with a | CT was c | oidosis w |
| of patier | 3-PET/C | ry of sarc |
| cteristics | 18F-FD(| ous histo |
| 1. Chara | SACE), | to previ |
| Table | zyme (| * refers |

| PatientSace AgeAge PalphlePalphle SACESACE OrganOrgan involvementRXPLN involvementSite involvementHauolosiFrande)Tenale)Tenale)Tenale)Tenale)SiteSite involvement< | | | | Clinical (| data | | | In | laging | Peripheral lym tech | ıph node nique | biopsy | Histologi | cal data |
|--|----------|---------------------------|--------------------------|----------------|-------------------------------------|--------------|--|-------------|--------------------------------------|------------------------|---------------------|---------------------------|-------------------------------------|--|
| 1True positiveM5501.5Spleen, parotid, eye2PositiveCervical3True positiveF471N01PositiveCervical4Tue positiveM3714Liver, spleen2PositiveCervical5True positiveM241N01PositiveCervical6True positiveF361NA01PositiveCervical7True positiveF5012PositiveCervicalName9True positiveF5012PositiveSpma-davicula10.*True positiveF5012PositiveSpma-davicula11True positiveF501N02PositiveSpma-davicula12True positiveF531N02PositiveSpma-davicula13True positiveF53115Liver, spleen1Spma-davicula14True positiveF53156Liver, spleen1Spma-davicula15True positiveF53156Liver, spleen1Spma-davicula16True positiveF53156Liver, spleen1Spma-davicula16True positiveF5311.5Sini, Liver, spleen1< | Patien | Histological Diagnosis | Sex (Male/ Female) | Age (Years) | Palpable PLN (Yes=1, No=0) | SACE (xN) | Organ involvement (extra-nodal and extra- pulmonary) | RX stage | PLN uptake on PET/CT (n=13) | Site | Samples (n= 71) | Needle size (Gauge) | Other biopsy sites | Diagnosis of granuloma (Positive) |
| 2 True positive F 191N ipe 1PositiveCervical 3^* True positiveM 3^* 1ALiver, spleen2PositiveCervical 5 True positiveM 3^* 1ASkin, sinus2PositiveCervical 6 True positiveF 3^* 1ASkin, sinus2PositiveCervical 7 True positiveF 3^* 1N 0 1PositiveEpirochleau 9 True positiveF 71 02PositiveEpirochleau 10^* True positiveF 71 0 2 PositiveEpirochleau 10^* True positiveF 50 1N 0 2 PositiveEpirochleau 10^* True positiveF 50 1N 0 2 PositiveSupar-divicula 11 True positiveF 50 1N 0 2 PositiveSupar-divicula 12 True positiveF 50 1N 0 2 PositiveSupar-divicula 16^* True positiveF 50 1 15 10^* 10^* 10^* 10^* 11^* True positiveF 50^* 10^* 10^* 10^* 10^* 10^* 10^* 16^* True positiveF 50^* 10^* 10^* 10^* 10^* | | True positive | M | 55 | 0 | 1.5 | Spleen, parotid, eye | 2 | Positive | Cervical | 2 | 16 | No | PLN |
| 3^* Thre positive F 47 1N $\dot{0}$ 1PositiveCervical 4 Thre positiveM 37 1 4 Liver, gleen 2 PositiveCervical 5 Thre positiveM 24 1 4 Skin, sinus 2 Cervical 6 Thre positiveF 36 1NA 0 1PositiveEpitochlea 7 Thre positiveF 36 1NA 0 1Supar-clavicula 8 Thre positiveF 50 12PositiveEpitochlea 9 Thre positiveF 50 1N 0 1Supar-clavicula 10^* Thre positiveF 50 1N 0 1Supar-clavicula 10^* Thre positiveF 50 1N 0 1 Supar-clavicula 10^* Thre positiveF 50 1 10^* 10^* 10^* 10^* Supar-clavicula 10^* Thre positiveF 50 11^* 10^* 10^* 10^* 10^* 10^* 11^* Thre positiveF 50^* 11^* 10^* 10^* 10^* 10^* 10^* 11^* Thre positiveF 50^* 11^* 10^* 10^* 10^* 10^* 10^* 12^* Thre positiveF 50^* 10^* 10^* 10^* 10^* 10^* 10 | 2 | True positive | ц | 19 | 1 | Z | Eye | 1 | | Cervical | 2 | 16 | EBB | PLN |
| 4True positiveM3714Liver, spleen2PositiveCervical5True positiveM2414Skin, sinus2Cervical6True positiveF361NA01PositiveEpitrochlea8True positiveF361NA01PositiveEpitrochlea9True positiveF5012PositiveEpitrochleaInguinal10.*True positiveF5012PositiveEpitrochlea11True positiveF501N9PositiveInguinal12True positiveF501N9PositiveSupra-clavicula13True positiveF53115.6Liver, spleen1PositiveSupra-clavicula14True positiveF5315.6Liver, spleen1PositiveSupra-clavicula16*True positiveF5312.5Skin, liver2PositiveCervical16True positiveF5312.5Skin, liver2PositiveCervical16True positiveF5312.5Skin, liver2PositiveCervical16True positiveF5312Skin, liver2PositiveCervical16True positiveF <t< td=""><td>3 *</td><td>True positive</td><td>Гц</td><td>47</td><td>1</td><td>Z</td><td>0 0</td><td>1</td><td>Positive</td><td>Cervical</td><td>1</td><td>16</td><td>EBB</td><td>PLN</td></t<> | 3 * | True positive | Гц | 47 | 1 | Z | 0 0 | 1 | Positive | Cervical | 1 | 16 | EBB | PLN |
| 5Tue positiveM2414Skin, sinus2Cervical7Tue positive F 361 NA 01 P P P 7Tue positive F 361 N 01 P P P 9Tue positive F 521 N 01 P P P 10*Tue positive F 501 N 0 2 P P P 10*Tue positive F 501 N D 2 P P P 11Tue positive F 501 N D 2 P P P 12Tue positive F 531 N D P P P P 13Tue positive F 531 N D P P P P 14Tue positive F 531 N D P P P P 15Tue positive F 531 N D P P P P 16*Tue positive F 531 N D P P P P 16*Tue positive F S D D D D P P P P 16*Tue positive F S D D D D D P P P | 4 | True positive | Μ | 37 | 1 | 4 | Liver, spleen | 2 | Positive | Cervical | 4 | 14 | Mediastinoscopy [®] EBB | Mediastinoscopy [*] PLN FRR |
| 6Tue positiveF361NA01Supra-clavicula7Tue positiveM4912Eye, parotid4PositiveEpitrochlea8Tue positiveF521N01Supra-clavicula10*Tue positiveF501N 0 2PositiveEpitrochlea10*Tue positiveF501NEye, joint02Supra-clavicula11Tue positiveF5211.5Liver, spleen1Supra-clavicula12Tue positiveF5311.5Liver, spleen1Supra-clavicula13Tue positiveF5312.5Eye, skin, liver2PositiveCervical16*Tue positiveF5312.5Eye, skin, liver2PositiveCervical16Tue positiveF531N001Cervical16Tue positiveF531N0NPositiveSupra-clavicula16Tue positiveF531N00Cervical17Tue positiveF531NPositiveNCervical18Tue positiveF531NPositivePositiveCervical19Tue positiveF2PositiveF2Positive <t< td=""><td>S</td><td>True positive</td><td>Μ</td><td>24</td><td>1</td><td>4</td><td>Skin, sinus</td><td>2</td><td></td><td>Cervical</td><td>3</td><td>18</td><td>EBB</td><td>PLN EBB</td></t<> | S | True positive | Μ | 24 | 1 | 4 | Skin, sinus | 2 | | Cervical | 3 | 18 | EBB | PLN EBB |
| 7Tue positiveM4912Bye, parotid4PositiveEpitrochlea8Tue positiveF521N01PositiveEpitrochlea10*Tue positiveF710202PositiveInguinal10*Tue positiveF711NEyc, joint04Supra-clavicula10*Tue positiveF711NEyc, joint09Supra-clavicula11Tue positiveF5211.5Liver, spleen1Supra-clavicula12Tue positiveF5312.5Eyc, skin, liver3PositiveSupra-clavicula13Tue positiveF5312.5Eyc, skin, liver2PositiveCervical14Tue positiveF5312.5Eyc, skin, liver2PositiveCervical16*Tue positiveF5312.5Eyc, skin, liver2PositiveCervical16Tue positiveF531N00NPositiveCervical17Tue positiveF531N00NPositiveCervical18Tue positiveF531N0NPositiveCervical19Tue positiveF531N2PositiveCervical <td< td=""><td>9</td><td>True positive</td><td>Ľ٦</td><td>36</td><td>1</td><td>NA</td><td>0</td><td>1</td><td></td><td>Supra-clavicular</td><td>3</td><td>16</td><td>MSG</td><td>PLN</td></td<> | 9 | True positive | Ľ٦ | 36 | 1 | NA | 0 | 1 | | Supra-clavicular | 3 | 16 | MSG | PLN |
| 8Tue positive F 521 N 0 1 1 9Tue positive F 7102 0 2Positive 1 10*Tue positive F 7102 0 2 $Positive$ 1 11Tue positive F 711 N Eyc_i joint 0 $Positive$ $Supra-davicula12Tue positiveF5311.5Liver, spleen1Supra-davicula13Tue positiveF531N02PositiveAxillary14Tue positiveF531N02PositiveAxillary15Tue positiveF531N02PositiveCervical16*Tue positiveF531N000Cervical16*Tue positiveF531N000Cervical16*Tue positiveF531N000Cervical17Tue positiveF531N000Cervical18Tue positiveF531N0NPositiveCervical19Tue positiveF531N000Cervical20Tue positiveF<$ | 7 | True positive | Μ | 49 | 1 | 2 | Eye, parotid | 4 | Positive | Epitrochlea | 3 | 18 | EBB | PLN |
| 9Tue positive F 710202PositiveInguinal10*Tue positive F 501 N $Eye, joint$ 0 4 Supra-clavicula11Tue positive F 521 1.5 $Liver, spleen$ 3 PositiveSupra-clavicula12Tue positive F 521 1.5 $Liver, spleen$ 3 PositiveAxillary13Tue positive F 531 2.5 $Eye, skin, liver$ 3 PositiveAxillary16*Tue positive F 531 2.5 $Eye, skin, liver$ 2 Positive $Cervical16*Tue positiveF5312.5Eye, skin, liver2PositiveCervical16*Tue positiveF531N00NCervical16*Tue positiveF531N00NCervical17Tue positiveF531N0NNCervical18Tue positiveF531N000Cervical19Tue positiveF531N0000Cervical20Tue positiveF281N0000021False negativeF281$ | ∞ | True positive | ГЦ | 52 | 1 | Z | 0 | 1 | | Inguinal | 4 | 16 | No | PLN |
| 10^* Tue positive F 50 1 N $Eye, joint$ 0 4 Supra-clavicula 11 True positive F 71 1 N $Eye, joint$ 0 $PositiveSupra-clavicula12True positiveF5211.5Liver, spleen1Supra-clavicula14True positiveF5315.6Liver, spleen1Supra-clavicula14True positiveF5312.5Eye, skin, liver2PositivePositive16^*True positiveF5312.5Eye, skin, liver2PositiveCervical16^*True positiveF5312.5Skin, Liver4PositiveCervical16^*True positiveF531N0NPP16^*True positiveF531N0NPP16^*True positiveF531N0NPP17True positiveM341N0NPPP16^*True positiveF531NNPPPP17True positiveF341NNPPPP$ | 6 | True positive | Гч | 71 | 0 | 2 | 0 | 2 | Positive | Inguinal | 4 | 18 | EBB MSG | PLN |
| 11Tue positive F 711NEye, joint0PositiveSupra-clavicula12True positive F 5211.5Liver3PositiveSupra-clavicula13True positive F 5815.6Liver, spleen1Supra-clavicula14True positive F 571N02Supra-clavicula15True positive F 5312.5Eye, skin, liver2PositiveCervical16*True positive F 531N00NACervical17True positive F 531N00NAPositiveCervical17True positive F 531N0NAPositiveCervical18True positive F 531NAPositiveSupra-clavicula19True positive F 531NAPositiveCervical20True positive F 291NAPositiveCervical21False negative F 281NASkinNAPositiveCervical22False negative F 290NAPositiveCervicalPositiveCervical23True positive F 290NAPositiveCervicalPositiveCervical23False negative F 29 </td <td>10^{*}</td> <td>True positive</td> <td>Гц</td> <td>50</td> <td>1</td> <td></td> <td>0</td> <td>4</td> <td></td> <td>Supra-clavicular</td> <td>4</td> <td>16</td> <td>EBB*</td> <td>PLN EBB*</td> | 10^{*} | True positive | Гц | 50 | 1 | | 0 | 4 | | Supra-clavicular | 4 | 16 | EBB* | PLN EBB* |
| 12The positive F 5211.5Liver, spleen3PositiveAxillary13True positive F 5815.6Liver, spleen1Supra-clavicula14True positive F 571 N 02Supra-clavicula15True positive F 531 2.5 Eye, skin, liver2PositiveCervical16*True positive F 281 2.5 Eye, skin, liver2Cervical16*True positive F 531 2.5 Eye, skin, liver4PositiveSupra-clavicula17True positive F 531 N 0 N N Cervical18True positive F 531 N 0 N N N N 19True positive F 531 N N N N N N 20True positive F 261 A 1.2 N N N N 21False negative F 281 N N N N N N N 22False negative F 281 N N N N N N | 11 | True positive | Гц | 71 | 1 | Z | Eye, joint | 0 | Positive | Supra-clavicular | 3 | 18 | EBB MSG | PLN |
| 13Tue positiveF5815.6Liver, spleen1Supra-clavicula14Tue positiveF571N02Cervical15Tue positiveF2812.5Eye, skin, liver2PositiveCervical16*Tue positiveM7201.5Skin, Liver4PositiveCervical16Tue positiveF531N00NAPositiveCervical17Tue positiveF531N0NAPositiveInguinal18True positiveF531NASiniveCervicalInguinal19True positiveF531NASiniveCervicalInguinal20Tue positiveF261NASiniveCervical21False negativeF281NASiniveCervical22False negativeF281NASiniveCervical23False negativeF281NASininalCervical | 12 | True positive | ĹŦ | 52 | 1 | 1.5 | Liver | 3 | Positive | Axillary | 3 | 18 | EBB | PLN |
| 14Tue positiveF 57 1N02Cervical15Tue positiveF2812.5Eye, skin, liver2PositiveCervical16*Tue positiveM7201.5Skin, Liver4PositiveCervical17True positiveF531N000Cervical18True positiveF531N00Cervical19True positiveF531NASinus2PositiveInguinal20True positiveF261NASinus2PositiveCervical21False negativeF2901.2Skin0PositiveInguinal22False negativeF281NASkinNACervical | 13 | True positive | ſц | 58 | 1 | 5.6 | Liver, spleen | 7 | | Supra-clavicular | 4 | 16 | EBB | PLN EBB |
| 15True positiveF2812.5Eye, skin, liver2PositiveCervical16*True positiveM7201.5Skin, Liver4PositiveCervical17True positiveF531N000Cervical18True positiveF53150NAPositiveInguinal19True positiveM341NASinus2PositiveCervical20True positiveF261ASinus2PositiveCervical21False negativeF281NASin0PositiveInguinal22False negativeF281NASinNACervical | 14 | True positive | ĹĿ | 57 | 1 | Z | 0 | 2 | | Cervical | 4 | 16 | No | PLN |
| 16^* True positiveM7201.5Skin, Liver4PositiveSupra-clavicula 17 True positiveF531N00Cervical 18 True positiveF53150NAPositiveInguinal 19 True positiveM341NASinus2PositiveCervical 20 True positiveF2614Liver, joint, Skin2PositiveCervical 21 False negativeF281NASkin0PositiveInguinal 22 False negativeF281NASkinNACervical | 15 | True positive | Гц | 28 | 1 | 2.5 | Eye, skin, liver | 2 | Positive | Cervical | 2 | 20 | EBB MSG | PLN MSG |
| 17True positiveF531N00Cervical18True positiveF53150NAPositiveInguinal19True positiveM341NASinus2PositiveCervical20True positiveF2614Liver, joint, Skin2PositiveCervical21False negativeF281NASkin0PositiveInguinal22False negativeF281NASkinNACervical | 16 * | True positive | Μ | 72 | 0 | 1.5 | Skin, Liver | 4 | Positive | Supra-clavicular | 2 | NA | EBB Mediastinosconv* | PLN FBB |
| 17True positiveF531N00Cervical18True positiveF53150NAPositiveInguinal19True positiveM341NASinus2PositiveCervical20True positiveF2614Liver, joint, Skin2PositiveCervical21False negativeF281NASkin0PositiveInguinal22False negativeF281NASkinNACervical | | | | | | | | | | | | 4 | (docomment) | Mediastinoscopy* |
| 18True positiveF53150NAPositiveInguial19True positiveM341NASinus2PositiveCervical20True positiveF2614Liver, joint, Skin2PositiveCervical21False negativeF281NASkin0PositiveInguial22False negativeF281NASkinNACervical | 17 | True positive | ΓĻ | 53 | 1 | Z | 0 | 0 | | Cervical | 9 | 14 | MSG | PLN |
| 19True positiveM341NASinus2PositiveCervical20True positiveF2614Liver, joint, Skin2PositiveCervical21False negativeF4901.2Skin0PositiveInguinal22False negativeF281NASkinNACervical | 18 | True positive | Гц | 53 | 1 | Ŋ | 0 | NA | Positive | Inguinal | NA | NA | EBB MSG | PLN |
| 20True positiveF2614Liver, joint, Skin2PositiveCervical21False negativeF4901.2Skin0PositiveInguinal22False negativeF281NASkinNACervical | 19 | True positive | Μ | 34 | 1 | NA | Sinus | 5 | Positive | Cervical | 9 | 16 | EBB Skin | PLN EBB Skin |
| 21False negativeF4901.2Skin0PositiveInguinal22False negativeF281NACervical | 20 | True positive | ц | 26 | 1 | 4 | Liver, joint, Skin | 2 | Positive | Cervical | 4 | 16 | No | PLN |
| 22 False negative F 28 1 NA Skin NA Cervical | 21 | False negative | ц | 49 | 0 | 1.2 | Skin | 0 | Positive | Inguinal | 3 | 16 | Skin | Skin |
| | 22 | False negative | Гц | 28 | 1 | NA | Skin | NA | | Cervical | 4 | 20 | Skin | Skin |

ed of 16 females and 6 males with a mean age of 46.4 (range, 19-72). Patients most often exhibited multiorgan involvement and serum angiotensin-converting enzyme dosage was ≥2N in 36% of cases. PLN biopsy was performed at presentation of sarcoidosis in 19 cases and to differentiate between flare-up/relapse or comorbid condition in 3 cases (Table 1). Eighteen patients had palpable PLN and 4 had clinically unapparent PLN that were detected by increased ^{18F}FDG-PET/CT uptake. A 16 Gauge needle was used in most cases (n=11). Biopsy was mainly performed on cervical (50%, n=11/22) and supraclavicular (23%, n=5/22) areas.

As shown in Table 1, it must be underscored that in 17 patients with PLN biopsies other tissue sampling was concurrently performed for the diagnosis. Among the 11 patients who underwent endobronchial biopsies and in the 5 cases who underwent minor salivary gland biopsy, PLN was the only site showing granulomas in 7/11 and 5/5 respectively.

DISCUSSION

This study demonstrates that the low-invasive US guided core-needle biopsy is a safe and highly efficient procedure, which may represent the most appropriate investigation to obtain granulomas face to suspected sarcoidosis with PLN. The sensitivity and positive predictive value for the diagnosis of sarcoidosis were found to be 91% and 99%, respectively. In addition, our study underscores that infra-clinical PLN detection through ^{18F}FDG-PET/CT also allows obtaining granulomas with this technique.

PLN biopsy has a long history in sarcoidosis. In the late 1950s, the surgical scalene lymph node biopsy was described by Daniels et al. (12) and proved to be an excellent method to obtain histological evidence of granulomas in sarcoidosis with a yield greater than 80% (13). Such surgical biopsies were performed even in the absence of palpable PLN but have been withdrawn in clinical practice with the generalization of mediastinoscopy. More recently, Lohela et al. proposed a new approach for supraclavicular lymph nodes through fine-needle aspiration cytology guided by US (9). Nowadays, fine-needle aspiration tends to be replaced by core-needle biopsy in most radiology departments, especially those dealing with hematologic patients, as it provides larger samples with possible analysis of lymph node architecture and immunostaining (6). Our results highlight the need to look carefully for PLN before more invasive investigations are proposed. Indeed, PLN biopsy performance seems as high as that reported for endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) (14-16).

In our study, we observed two patients classified as false positive. These patients had a histological diagnosis of granulomas without caseating necrosis, but tuberculosis was the final diagnosis (mycobacterial culture from the PLN biopsy was positive in both cases). Such observation confirms the importance of always combining mycobacterial culture with histological results in patients at risk for tuberculosis transmission. Moreover, a special attention should be paid during ultrasound examination which could alert for tuberculosis. Features suggestive of tuberculosis have been well described during EBUS, including coagulation necrosis and heterogeneous echotexture (17, 18). Finally, the risk of false positive results highlights the need to exclude all other causes of granulomas before a diagnosis of sarcoidosis can be ascertained (19, 20). Indeed, since the presence of sarcoid-like granulomas in a PLN may also result from a reaction to a nearby malignant tumour (including lymphoma) or inflammatory disease, the quality of biopsy samples is critical, especially when PLN develops late after the diagnosis of sarcoidosis.

The main limitations of our study are due to its mono-centric and retrospective design. Because Avicenne Hospital is a third care centre for sarcoidosis, this disease is overrepresented in our population of PLN biopsies (8%), with a higher proportion than expected according to the literature (7).

Conclusions

Our results confirm that core-needle biopsy guided by US in patients with PLNs should be considered as a first intention technique for the diagnosis of sarcoidosis (either at initial diagnosis or relapse), besides skin lesions or visible conjunctival nodules biopsy. This technique could be proposed before more invasive investigations in patients with palpable PLN or increased PLN uptake on ^{18F}FDG-PET/CT.

References

- Baughman RP, Culver DA, Judson MA. A concise review of pulmonary sarcoidosis. Am J Respir Crit Care Med 2011; 183: 573-581.
- 2. Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lancet 2014; 383: 1155-1167.
- Teirstein AS, Judson MA, Baughman RP, et al. The spectrum of biopsy sites for the diagnosis of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: 139-146.
- Costabel U. Sarcoidosis: clinical update. Eur Respir J Suppl 2001; 32: 56s-68s.
- 5. Yanardag H, Caner M, Papila I, et al. Diagnostic value of peripheral lymph node biopsy in sarcoidosis: a report of 67 cases. Can Respir J 2007; 14: 209-211.
- de Kerviler E, de Bazelaire C, Mounier N, et al. Image-guided coreneedle biopsy of peripheral lymph nodes allows the diagnosis of lymphomas. Eur Radiol 2007; 17: 843-849.
- Pfeiffer J, Kayser G, Ridder GJ. Sonography-assisted cutting needle biopsy in the head and neck for the diagnosis of lymphoma: can it replace lymph node extirpation? Laryngoscope 2009; 119: 689-695.
- Fultz PJ, Harrow AR, Elvey SP, et al. Sonographically guided biopsy of supraclavicular lymph nodes: a simple alternative to lung biopsy and other more invasive procedures. AJR Am J Roentgenol 2003; 180: 1403-1409.
- Lohela P, Tikkakoski T, Strengell L, et al. Ultrasound-guided fineneedle aspiration cytology of non-palpable supraclavicular lymph nodes in sarcoidosis. Acta Radiol 1996; 37: 896-899.
- Teirstein AS, Machac J, Almeida O, et al. Results of 188 whole-body fluorodeoxyglucose positron emission tomography scans in 137 patients with sarcoidosis. Chest 2007; 132: 1949-1953.

- 11. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160: 736-755.
- 12. Daniels AC: A method of biopsy useful in diagnosing certain intrathoracic disease. Dis Chest 1949; 16: 360-367.
- Truedson H, Stjernberg N, Thunell M. Scalene lymph node biopsy. A diagnostic method in sarcoidosis. Acta Chir Scand 1985; 151: 121-123.
- Gupta D, Dadhwal DS, Agarwal R, et al. Endobronchial Ultrasound Guided TBNA vs. Conventional TBNA in the diagnosis of sarcoidosis. Chest 2014.
- Navani N, Booth HL, Kocjan G, et al. Combination of endobronchial ultrasound-guided transbronchial needle aspiration with standard bronchoscopic techniques for the diagnosis of stage I and stage II pulmonary sarcoidosis. Respirology 2011; 16: 467-472.
- Agarwal R, Srinivasan A, Aggarwal AN, et al. Efficacy and safety of convex probe EBUS-TBNA in sarcoidosis: a systematic review and meta-analysis. Respir Med 2012; 106: 883-892.
- Berim I, Dhillon S. Coagulation necrosis sign on endobronchial ultrasound. Am J Respir Crit Care Med 2012; 185:e6.
- Dhooria S, Agarwal R, Aggarwal AN, et al. Differentiating tuberculosis from sarcoidosis by sonographic characteristics of lymph nodes on endobronchial ultrasonography: A study of 165 patients. J Thorac Cardiovasc Surg 2014.
- Brincker H. Sarcoidosis and malignancy. Chest 1995; 108: 1472-1474.
- Spagnolo P, Luppi F, Roversi P, et al. Sarcoidosis: challenging diagnostic aspects of an old disease. Am J Med 2012; 125: 118-125.